We are live on !
Find out more
EAM
Empery Asset Management Portfolio holdings
AUM
$86.5M
Turnover
51.16%
This Fund
S&P 500
This Quarter Est. Return
+11.7%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$86.5M
AUM Growth
+$3.46M
(+4.2%)
Cap. Flow
+$4.95M
Cap. Flow % of AUM
Cap. Flow %
5.73%
Top 10 Holdings %
Top 10 Hldgs %
90.67%
Holding
43
New
11
Increased
–
Reduced
8
Closed
11
Avg Time Held
1.2
years
Top 10 Avg Time Held
0.2
years
Top 20 Avg Time Held
0.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NervGen Pharma
NGEN
|
+$12.4M |
| 2 |
Clene
CLNN
|
+$5.71M |
| 3 |
Annovis Bio
ANVS
|
+$4.67M |
| 4 |
One and One Green Technologies
YDDL
|
+$3.59M |
| 5 |
AMC Entertainment Holdings
AMC
|
+$2.95M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Precision BioSciences
DTIL
|
+$8.39M |
| 2 |
X4 Pharmaceuticals
XFOR
|
+$8.26M |
| 3 |
Imperial Petroleum
IMPP
|
+$3.76M |
| 4 |
Venu Holding Corp
VENU
|
+$1.77M |
| 5 |
Big Sky Industrial
BSIN
|
+$1.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 69.15% |
| 2 | Consumer Discretionary | 12.06% |
| 3 | Consumer Staples | 6.52% |
| 4 | Communication Services | 5.11% |
| 5 | Materials | 1.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
X4 Pharmaceuticals
XFOR
$301M
| $32.4M | 37.43% |
6,930,591
-2,013,527
| -23% | -$8.26M |
2025 Q4
2 quarters
|
|
2
Empery Digital
EMPD
$88.2M
| $10.4M | 12.06% |
2,930,345
| – | – |
2025 Q4
2 quarters
|
|
|
3
NervGen Pharma
NGEN
$165M
| $8.24M | 9.53% |
+4,000,000
| New | +$12.4M |
2026 Q2
0 quarters
|
|
|
4
Precision BioSciences
DTIL
$182M
| $6.1M | 7.05% |
776,093
-1,192,786
| -61% | -$8.39M |
2025 Q4
2 quarters
|
|
|
5
Clene
CLNN
$53.9M
| $5.64M | 6.52% |
+916,532
| New | +$5.71M |
2026 Q2
0 quarters
|
|
|
6
Annovis Bio
ANVS
$41.9M
| $4.47M | 5.17% |
+2,401,476
| New | +$4.67M |
2026 Q2
0 quarters
|
|
7
Lantern Pharma
LTRN
$10.6M
| $3.51M | 4.06% |
+842,669
| New | +$2.47M |
2026 Q2
0 quarters
|
|
|
8
AMC Entertainment Holdings
AMC
$2.71B
| $3.26M | 3.77% |
+1,714,043
| New | +$2.95M |
2026 Q2
0 quarters
|
|
9
Tenaya Therapeutics
TNYA
$92.8M
| $2.86M | 3.3% |
3,863,115
-423,818
| -10% | -$322K |
2025 Q4
2 quarters
|
|
|
10
One and One Green Technologies
YDDL
$68.9M
| $1.54M | 1.78% |
+761,706
| New | +$3.59M |
2026 Q2
0 quarters
|
|
11
Cyngn
CYN
$6.28M
| $1.29M | 1.49% |
927,059
-30,725
| -3% | -$45.5K |
2026 Q1
1 quarter
|
|
|
12
Venu Holding Corp
VENU
$71.8M
| $1.16M | 1.35% |
512,818
-494,911
| -49% | -$1.77M |
2026 Q1
1 quarter
|
|
13
Greenland Energy Company Warrant
GLNDW
$7.53M
| $850K | 0.98% |
+1,000,000
| New | +$1.09M |
2026 Q2
0 quarters
|
|
14
Ur-Energy
URG
$324M
| $843K | 0.98% |
620,136
| – | – |
2026 Q1
1 quarter
|
|
15
Satellos Bioscience
MSLE
$145M
| $833K | 0.96% |
107,100
-123,000
| -53% | -$845K |
2026 Q1
1 quarter
|
|
16
Jaguar Uranium Corp
JAGU
$20.2M
| $814K | 0.94% |
487,500
| – | – |
2026 Q1
1 quarter
|
|
17
Cellectar Biosciences
CLRB
$11.4M
| $527K | 0.61% |
+189,605
| New | +$530K |
2026 Q2
0 quarters
|
|
18
SCYNEXIS
SCYX
$38M
| $515K | 0.6% |
126,451
-104,527
| -45% | -$649K |
2026 Q1
1 quarter
|
|
19
Rein Therapeutics
RNTX
$50.3M
| $386K | 0.45% |
+370,834
| New | +$449K |
2026 Q2
0 quarters
|
|
20
BTC Digital
BTCT
$13M
| $289K | 0.33% |
+350,877
| New | +$415K |
2026 Q2
0 quarters
|
|
21
BriaCell Therapeutics Warrant
BCTXL
$2.51M
| $267K | 0.31% |
300,000
| – | – |
2026 Q1
1 quarter
|
|
22
Maris-Tech Ltd Warrants
MTEKW
| $58K | 0.07% |
297,600
| – | – |
2022 Q1
17 quarters
|
|
23
ParaZero Technologies
PRZO
$15.4M
| $55.3K | 0.06% |
113,771
-168,428
| -60% | -$109K |
2026 Q1
1 quarter
|
|
24
DUKE Robotics Warrant
DUKRW
$914K
| $45.2K | 0.05% |
+35,000
| New | +$57K |
2026 Q2
0 quarters
|
|
25
DELISTED
Nutriband Inc Warrant
NTRBW
| $40.2K | 0.05% |
40,218
| – | – |
2021 Q4
18 quarters
|
|
Similar funds
BCM
TI
AA
RCSA
YAG
CL
TWM
BI
Empery Asset Management's Q2 2026 Portfolio in Review
As of Q2 2026, Empery Asset Management held 43 positions worth $86.5M, up 4.2% from $83M the previous quarter. Its ten largest holdings account for 91% of the portfolio.
Empery Asset Management deployed $4.95M of net new capital in Q2 2026, opening 11 new positions. Its largest new stake was NervGen Pharma: 4,000,000 shares worth $8.24M.
By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 67% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.
On the sell side, the largest reduction was Precision BioSciences, an estimated $8.39M trimmed.
- Empery Asset Management's largest Q2 2026 buy was NervGen Pharma: 4,000,000 shares worth $8.24M.
- Empery Asset Management's biggest Q2 2026 reduction was Precision BioSciences, cutting an estimated $8.39M.
- Empery Asset Management fully exited Imperial Petroleum in Q2 2026, selling an estimated $3.76M.
- Empery Asset Management's ten largest holdings make up 91% of its $86.5M portfolio in Q2 2026.
- Empery Asset Management opened 11 new positions and closed 11 in Q2 2026.
- Empery Asset Management's portfolio value rose 4.2% quarter-over-quarter to $86.5M.
Based on Empery Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.